Fig. 1 · Structure
Documents & Downloads
EVT0185
ACLY Inhibitor
EVT0185 is an orally active inhibitor of ATP citrate lyase (ACLY). Through conversion to a CoA thioester by SLC27A2 in the liver, EVT0185 exhibits its inhibitory effects by binding to the CoA-binding site of ACLY, achieving an IC50 of 2.5 μM. This compound mimics the immune and antitumor effects associated with genetic ACLY deletion, enhancing tumor-infiltrating B cells and increasing levels of chemokine CXCL13. EVT0185 is relevant for research into various cancers, particularly hepatocellular carcinoma (HCC).
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 2588489-03-4 |
| Applications | ACLY Inhibitor |
| Formula | C22H34O4 |
| Molecular Weight | 362.50 |
| SMILES | O=C(O)C(C)(C)CCCCC1=CC=C(CCCCC(C)(C(O)=O)C)C=C1 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.